LETTER TO THE EDITOR

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine

Hiroshi Handa¹, June-Won Cheong², Yasushi Onishi³, Hiroatsu Iida⁴, Yukio Kobayashi⁵, Hyeoung-Joon Kim⁶, Tzeon-Jye Chiou⁷, Koji Izutsu⁸, Olga Tsukurov⁹, Xiaofei Zhou⁹, Helene Faessel⁹, Ying Yuan⁹, Farhad Sedarati⁹, Douglas V. Faller⁹, Akiko Kimura¹⁰ and Shang-Ju Wu¹¹*

Prior publications: Wu S-J, et al. Hemasphere 2018;2(S1):446 (abstract PS997). Handa H, et al. Oral presentation O1-12-1 at the 2018 Japanese Society of Medical Oncology (JSMO) Annual Meeting.

Abstract

Pevonedistat, the first small-molecule inhibitor of NEDD8-activating enzyme, has demonstrated clinical activity in Western patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We report findings from a phase 1/1b study in East Asian patients with AML or MDS, conducted to evaluate the safety/tolerability and characterize the pharmacokinetics of pevonedistat, alone or in combination with azacitidine, in this population, and determine the recommended phase 2/3 dose for pevonedistat plus azacitidine. Twenty-three adult patients with very high/high/intermediate-risk AML or MDS were enrolled in Japan, South Korea and Taiwan. All 23 patients experienced at least one grade ≥ 3 treatment-emergent adverse event. One patient in the combination cohort reported a dose-limiting toxicity. Eighteen patients discontinued treatment; in nine patients, discontinuation was due to progressive disease. Three patients died on study of causes considered unrelated to study drugs. Pevonedistat exhibited linear pharmacokinetics over the dose range of 10–44 mg/m², with minimal accumulation following multiple-dose administration. An objective response was achieved by 5/11 (45%) response-evaluable patients in the pevonedistat plus azacitidine arm (all with AML), and 0 in the single-agent pevonedistat arm. This study showed that the pharmacokinetic and safety profiles of pevonedistat plus azacitidine in East Asian patients were similar to those observed in Western patients as previously reported. The recommended Phase 2/3 dose (RP2/3D) of pevonedistat was determined to be 20 mg/m² for co-administration with azacitidine 75 mg/m² in Phase 2/3 studies, which was identical to the RP2/3D established in Western patients.

*Correspondence: wushangju@ntu.edu.tw
¹¹ Division of Hematology, Department of Internal Medicine, Zhongzheng Dist, National Taiwan University Hospital, No.7, Zhongshan S. Rd., Taipei City 100, Taiwan

Full list of author information is available at the end of the article
To the Editor

There is a critical unmet need for novel treatment options that can improve outcomes in patients with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). Pevonedistat (MLN4924; TAK-924) is an investigational small-molecule inhibitor of neural precursor cell expressed, developmentally downregulated 8 (NEDD8)-activating enzyme (NAE) [1–3]. Upregulation of the NEDD8 cascade is associated with cancer pathogenesis, making it a compelling target for drug development [4, 5]. Pevonedistat forms an adduct with NAE, preventing activation of the cascade and ultimately leading to substrate accumulation and cell death. A phase 1b study of pevonedistat and azacitidine combination treatment conducted in Western patients aged ≥ 60 years with untreated AML showed that the combination was well tolerated and exhibited clinical activity, with an objective response rate (ORR) of 50% [6]. The recommended phase 2/3 dose (RP2/3D) of pevonedistat for co-administration with azacitidine was determined to be 20 mg/m².

Pharmacokinetics (PK) can differ between Asian and Western patients. We conducted an open-label phase 1/1b dose escalation/expansion study (NCT02782468) to assess the safety/tolerability and PK of pevonedistat as a single agent or in combination with azacitidine in East Asian patients with AML or higher-risk MDS, and to determine the RP2/3D for combination treatment in this population. Full study design and methods are provided in Additional file 1.

A total of 23 patients were enrolled in Japan, South Korea and Taiwan (n = 12/4/7). Ten patients received single-agent pevonedistat 25 mg/m² or 44 mg/m² (n = 3/7), and 13 patients received pevonedistat 10 mg/m².

### Table 1. Overall summary of TEAEs (safety population)

|                    | Pevonedistat | Pevonedistat + azacitidine 75 mg/m² | Total |
|--------------------|--------------|-------------------------------------|-------|
|                    | 25 mg/m²     | 44 mg/m²                            | Total |
| n = 3 N            | 3 (100)      | 7 (100)                             | 10 (100) |
| Grade ≥ 3a         | 3 (100)      | 7 (100)                             | 10 (100) |
| Grade ≥ 4a         | 0            | 2 (28)                              | 2 (20) |
| Any drug-related TEAE | 3 (100)     | 3 (100)                             | 6 (60) |
| Grade ≥ 3a         | 2 (67)       | 2 (29)                              | 4 (40) |
| SAE                | 2 (67)       | 7 (100)                             | 9 (90) |
| Drug-related SAE   | 0            | 1 (14)                              | 1 (10) |
| TEAEs resulting in study drug discontinuation | 0         | 2 (29)                              | 2 (20) |
| TEAEs resulting in discontinuation from the study | 0         | 3 (43)                              | 3 (30) |
| On-study deathsb   | 0            | 1 (14)                              | 1 (10) |

SAE, serious adverse event; TEAE, treatment-emergent adverse event

TEAE was defined as any adverse event that occurred after administration of the first dose of study treatment and up through 30 days after the last dose of study drug, any event that was considered drug related regardless of the start date of the event, or any event that was present at baseline but worsened in severity after baseline. Percentages are based on the total number of patients in safety population in each column. A patient counts once for each event

a Individual grades represent the maximum severity a patient experienced
b On-study deaths were defined as deaths that occurred between the first dose of study drug and 30 days after the last dose of study drug

AML, pneumonia and acute kidney injury (n = 1 each); no on-study deaths were attributed to study treatments

Trial registration: clinicaltrials.gov: NCT02782468 25 May 2016. https://clinicaltrials.gov/ct2/show/NCT02782468

Keywords: AML, MDS, Pevonedistat, Phase 1/1b, East Asian
m² or 20 mg/m² (n = 3/10) plus azacitidine 75 mg/m². Patient demographics and disease characteristics are shown in Additional file 1: Table S1. At data cut-off, 5 patients remained on combination treatment, while 18 had discontinued study treatment, primarily due to progressive disease (PD; n = 9) or adverse events (AEs; n = 6).

Safety

All 23 patients experienced at least one grade ≥ 3 treatment-emergent AE (TEAE). The safety profile of pevonedistat with/without azacitidine in East Asian patients (summarized in Table 1) was comparable to that in Western patients [6, 7], with the most common TEAEs including constipation, nausea, and anemia (Additional file 1: Table S2).

Only one of twenty evaluable patients experienced DLTs: One patient receiving pevonedistat 20 mg/m² plus azacitidine experienced grade 3 atrial fibrillation and grade 3 tumor lysis syndrome. The RP2/3D of pevonedistat in combination with azacitidine was therefore determined to be 20 mg/m².

Pevonedistat PK

Pevonedistat PK data (summarized in Additional file 1: Table S3) showed that systemic exposure increased in an approximately dose-proportional manner over the 10–44 mg/m² dose range. There was minimal accumulation following multiple-dose administration, consistent with the mean terminal disposition phase half-life (T₁/₂) of approximately 8 h. Clearance rates were comparable for pevonedistat as a single agent and when co-administered with azacitidine, suggesting that co-administration has no clinically meaningful effects on pevonedistat exposure. These findings were consistent with previous analyses of pevonedistat PK in Western patients (Additional file 1: Table S4) [6–9].

Antitumor activity

Treatment duration and responses for the 19 evaluable patients are illustrated in Fig. 1a. ORRs were 0% in the single-agent pevonedistat arm (N = 8) and 45% in the pevonedistat plus azacitidine arm (N = 11; Additional file 1: Table S5). The median duration of response in the 5 responding patients, all of whom had AML, was 4.8 months (range 1–14 months) at data cut-off. The majority of patients with MDS (N = 6) had stable disease (n = 4), while one achieved marrow complete remission (mCR) and one had PD (Additional file 1: Table S5). Changes from baseline in myeloblast count in patients with AML and MDS are shown in Fig. 1b, c.

In summary, the safety and PK profiles of pevonedistat in East Asian patients were consistent with those seen in Western patients. Clinical activity was demonstrated, with an ORR of 45% in East Asian patients with AML treated with pevonedistat plus azacitidine. The RP2/3D for pevonedistat in combination with azacitidine was 20 mg/m², the same as that previously determined in Western patients [6]. This supports use of the same treatment regimens in Western and East Asian patients in future global trials.

(See figure on next page.)

Fig. 1 Treatment responses in the response-evaluable populationa (N = 19): a Swimmer plot showing responses and duration of treatmentb; Best percentage change from baseline in myeloblast count in b patients with AML and c patients with MDS. AE, adverse event; AML, acute myeloid leukemia; CB, clinical benefit; CR, complete remission; CRi, complete remission with incomplete blood count recovery; HSCT, hematopoietic stem cell transplant; mCR, marrow complete remission; MDS, myelodysplastic syndromes; PD, progressive disease; PR, partial remission; SD, stable disease. aAll patients who received at least one dose of study drug, had a baseline disease assessment, and had at least one post-baseline disease assessment. bFor patients who were ongoing treatment at data cut-off and who therefore did not have a date of last visit, their date of last assessment was used to determine bar length. TP53 mutation status is indicated for the 4 patients with available data. Mutation status was unknown in the remaining patients. cTwo patients with AML in the single-agent pevonedistat 44 mg/m² dose cohort and one patient with AML in the pevonedistat 10 mg/m² combination arm dose cohort were excluded due to insufficient bone marrow aspirate blast data. The patient with AML with a decrease in blast count and stable disease had an abnormal cytogenetic finding at screening; stable disease was recorded on cycle 1 day 15 on November 27, 2017, and lasted to the end of study on December 7, 2017. The patient discontinued the study to initiate a hematopoietic stem cell transplant. dOne patient with MDS in the pevonedistat 20 mg/m² combination arm dose cohort was excluded due to insufficient bone marrow aspirate blast data.
Fig. 1 (See legend on previous page.)
which may help expedite access to pevonedistat-based treatment in Asia.

Abbreviations
AE: Adverse event; (Allo‑)HSCT: (Allogeneic) hematopoietic stem cell transplantation; AML: Acute myeloid leukemia; CR: Complete remission; CRi: Complete remission with incomplete blood count recovery; DLT: Dose-limiting toxicity; HI: Hematologic improvement; mCR: Marrow complete remission; MDS: Myelodysplastic syndromes; NAE: NEDD8‑activating enzyme; NEDD8: Neural precursor cell expressed developmentally down‑regulated protein 8; ORR: Objective response rate; PD: Progressive disease; RRM2: Ribonucleotide reductase; SAE: Serious adverse event; SD: Stable disease; T1/2z: Terminal disposition phase half‑life; TEAE: Treatment‑emergent adverse event.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13045‑022‑01264‑w.

Additional file 1. Supplementary methods, tables, and figure.

Acknowledgements
The authors would like to acknowledge all patients who participated in this study and their families, as well as all the investigators and site staff who made the study possible. We thank Qiang Wang from PPD, who served as the medical monitor for this study. The authors acknowledge Helen Kitchen, PhD, and Helen Wilkinson, PhD, of Ashfield MedComms, an Ashfield Health company, for medical writing support for the development of this manuscript under the direction of the authors, which was funded by Takeda Pharmaceuticals, U.S.A., Inc., and complied with the Good Publication Practice 3 ethical guidelines (Battisti WP, et al. Ann Intern Med 2015;163:461–4), and editorial support from Marcel Kuttab, PharmD (Takeda Pharmaceuticals U.S.A., Inc.).

Author contributions
J‑WC, YO, YK, H‑JK, T‑JC, XZ, FS, AK, and S‑JW contributed to the conception of the work. YK, XZ, YY, and FS designed the work. J‑WC, HI, H‑JK, KL, OT, and XZ acquired and analyzed the data. HH, YO, YK, H‑JK, T‑JC, KL, XZ, HF, YY, FS, AK, and S‑JW interpreted the data. All authors drafted or substantially revised the work, provided approval of the final submitted version of the manuscript and have agreed to be accountable for all aspects of the work. All authors read and approved the final manuscript.

Funding
This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Availability of data and materials
The datasets, including the redacted study protocol, redacted statistical analysis plan and individual participants data supporting the results reported in this article, will be made available within 3 months from initial request, to researchers who provide a methodologically sound proposal. The datasets will be provided after its de‑identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization.

Declarations
Ethics approval and consent to participate
Institutional review boards at all sites approved the study, which was conducted according to the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice, and applicable regional or local regulations. All patients provided written informed consent.

Consent for publication
Not applicable.

Competing interests
Hiroshi Handa has received honoraria, consulting fees and grants/funds from Takeda. Yasushi Onishi has received honoraria from Novartis and Pfizer, and grants/funds from Takeda, Novartis, MSD and Janssen. Hirotatsu Ide has received honoraria from Novartis, Janssen, Celgene and Astellas, and grants/funds from Chugai. Yukio Kobayashi has participated on an advisory council/committee for Symbo. Koji Izu has received honoraria, consulting fees and grants/funds from Takeda. Xiaofei Zhou is employed by Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda. Helene Faessel is employed by, and owns stocks/shares in, Takeda. Ying Yuan, Farhad Sedarati and Akiko Kimura are employed by Takeda. The other authors declare that they have no competing interests.

Author details
1 National University Corporation, Gunma University, Maebashi, Japan. 2 Sever‑lent Hospital, Yonsei University Health System, Seoul, South Korea. 3 National University Corporation Tohoku University, Sendai, Japan. 4 National Hospital Organization Nagoya Medical Center, Nagoya, Japan. 5 International University of Health and Welfare, Mita Hospital, Tokyo, Japan. 6 Chonnam National University Hospital, Hwasun Hospital, Hwasun, South Korea. 7 Taipei Municipal Wanfang Hospital, Taipei Medical University, Taipei Veterans General Hospital, Taipei, Taiwan. 8 National Cancer Center Hospital, Tokyo, Japan. 9 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA. 10 Takeda Pharmacetical Company Limited, Osaka, Japan. 11 Division of Hematology, Department of Internal Medicine, Zhongzheng Dist, National Taiwan University Hospital, No.7, Zhongshan S. Rd., Taipei City 100, Taiwan.

Received: 3 February 2022 Accepted: 18 April 2022
Published online: 11 May 2022

References
1. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzese FJ, Bump NJ, et al. Substrate‑assisted inhibition of ubiquitin‑like protein‑activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8‑AIP mimerin in situ. Mol Cell. 2010;37(1):102–11.
2. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, et al. Inhibition of NEDD8‑activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010;115(18):3796–800.
3. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8‑activating enzyme as a new approach to treat cancer. Nature. 2009;458(7239):732–6.
4. Nawrocki ST, Griffin P, Kelly KR, Carew JS. MLN4924: a novel first‑in‑class inhibitor of NEDD8‑activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012;21(10):1563‑73.
5. Milhollen MA, Traore T, Adams‑Duffey J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8‑activating enzyme inhibitor, is active in diffuse large B‑cell lymphoma models: rationale for treatment of NF‑κB‑dependent lymphoma. Blood. 2010;116(9):1515–23.
6. Swords RT, Court S, Maris MB, Zeidner JF, Foran JM, Cruz J, et al. Pevonedistat, a first‑in‑class NEDD8‑activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018;131(13):1415–24.
7. Swords RT, Erba HP, Deangelio DJ, Bikby DL, Altman JK, Maris M, et al. Pevonedistat (MLN4924), a first‑in‑class NEDD8‑activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol. 2015;169(4):534–43.
8. Swords RT, Watts J, Erba HP, Altman JK, Maris M, Anwer F, et al. Expanded safety analysis of pevonedistat, a first‑in‑class NEDD8‑activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer J. 2017;7(2):e520.
9. Faessel HM, Mould DR, Zhou X, Fuller DV, Sedarati F, Venkatakrishnan K. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. Br J Clin Pharmacol. 2019;85(11):2568–79.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.